Gilead announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted an opinion recommending Trodelvy as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. The final European Commission decision on the additional indication for Trodelvy is anticipated later in 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Gilead announces Week 96 results from MYR301 clinical trial
- Gilead announces completion of marketing authorization in Japan for Yescarta
- Galapagos appoints Thad Huston as CFO and COO as of July 1
- Gilead Sciences Strikes New Deal with Arcus Biosciences
- Gilead call volume above normal and directionally bullish